Table 2:

Clinical response to MDCF-2 or RUSF supplementation

Anthropometry at the start of intervention i.e. baseline
	MDCF-2 (n=59)†	RUSF (n=59)†	β Treatment (95% CI)‡
WLZ	−2.22 ± 0.39	−2.29 ± 0.36	0.086 (−0.056, 0.228)
WAZ	−2.66 ± 0.67	−2.71 ± 0.64	0.036 (−0.213, 0.285)
LAZ	−2.14 ± 1.14	−2.13 ± 1.13	−0.044 (−0.467, 0.380)
MUAC (cm)	12.8 ± 0.51	12.7 ± 0.44	0.077 (−0.100, 0.254)
Rate of growth during intervention (Δ anthropometry/week)
	β growth rate for MDCF-2 (95% CI)§	β growth rate for RUSF (95% CI)§	β Interaction (95% CI)¤
WLZ	0.021 (0.014, 0.029)	0.010 (0.003, 0.017)	0.011 (0.001, 0.021)
WAZ	0.017 (0.012, 0.022)	0.010 (0.004, 0.015)	0.008 (0.001, 0.015)
LAZ	0.004 (0.002, 0.007)	0.005 (0.003, 0.008)	−0.001 (−0.005, 0.003)
MUAC (cm)	0.031 (0.029, 0.034)	0.029 (0.025, 0.032)	0.003 (−0.001, 0.007)
Rate of growth including the 1-month follow-up (Δ anthropometry/week)
	β growth rate for MDCF-2 (95% CI)§	β growth rate for RUSF (95% CI)§	β Interaction (95% CI)¤
WLZ	0.010 (0.005, 0.016)	0.000 (−0.005, 0.006)	0.010 (0.002, 0.018)
WAZ	0.009 (0.005, 0.013)	0.001 (−0.003, 0.005)	0.008 (0.002, 0.013)
LAZ	0.004 (0.002, 0.006)	0.003 (0.001, 0.006)	0.000 (−0.003, 0.003)
MUAC (cm)	0.028 (0.026, 0.031)	0.024 (0.022, 0.027)	0.004 (0.000, 0.007)

^†Values represent the mean ± SD.

^‡Linear model predicting anthropometry at the start of the intervention as a function of treatment group, controlling for baseline age, gender and any illness 7 days prior to starting the intervention. β indicates the mean difference in anthropometry between participants who were assigned to the MDCF-2 and RUSF arms at the start of the intervention. CI, confidence interval.

^§Mixed effects linear model predicting anthropometry as a function of weeks since starting nutritional supplementation, controlling for the main effects of baseline age, gender, any illness 7 days prior to starting the intervention, and a random intercept for each participant. β indicates the growth rate in unit (anthropometric measure) per week.

^¤Mixed effects linear model predicting anthropometry as a function of the interaction between treatment group and weeks since starting nutritional supplementation, controlling for the main effects of baseline age, gender, any illness 7 days prior to starting the intervention, weeks in the intervention, treatment group, and a random intercept for each participant. β indicates the interaction between treatment and growth rate in unit/week (a positive value indicates a faster growth rate in children receiving MDCF-2).